Post‑approval M&A timing data

A strange thing happens when a biotech company finally gets a drug through the FDA. You might expect that approval to mark the start of a long independent life as a commercial business. In many cases, it does the opposite. An analysis of commercial-stage biotech exits now suggests that once a company gets its first FDA approval, the clock to a sale runs fast. Roughly 88% of those companies are acquired within about 33 months. The point is not subtle. In biotech, a first approval often does not open a new chapter. It starts the endgame. That result fits the industry’s structure. Large drugmakers have spent years leaning on acquisitions to refill pipelines, add marketed products, and buy their way into hot categories. BioPharma Dive’s running deal tracker shows the pattern in plain sight. Big pharma keeps buying smaller companies for approved drugs, near-launch assets, and the commercial teams that come with them. Dealmaking slowed in 2021 and 2022, then picked up again as buyers returned for oncology, rare disease, immunology, obesity, and newer platform technologies. (biopharmadive.com) What makes the new timing data useful is that it narrows the moment when value seems to crystallize. Approval has always mattered. It removes the biggest binary risk in drug development. The FDA’s own outline of the process makes clear why. Years of discovery, preclinical work, and clinical testing all funnel into review, and only after approval does a product enter post-market monitoring. (fda.gov) But the analysis argues that the market is not just rewarding approval in theory. It is rewarding it quickly, and often through a sale rather than through a long period of stand-alone execution. That matters because the work after approval is not light cleanup. It is a new regulatory phase with its own hazards. FDA post-market oversight continues after launch. So do manufacturing inspections, labeling updates, safety signal detection, supplemental filings, and chemistry, manufacturing, and controls changes. FDA materials on lifecycle management describe post-approval changes as routine and often risk-based, spanning site changes, process changes, new indications, safety labeling changes, and other supplements that can arrive on tight review clocks. (fda.gov) The company may be newly commercial, but it is still living inside a dense regulatory system. That is where the timing becomes operational, not just financial. If most commercial-stage biotech companies that get sold are gone within roughly three years of approval, leaders have less time to build the kind of mature safety and quality infrastructure that a permanent independent company might assume it needs. They still need pharmacovigilance systems that work on day one. They still need inspection readiness. They still need fast escalation paths for deviations, complaints, and emerging risks. But the incentive shifts. The goal is less about building a ten-year standalone machine and more about proving the asset, the label, the supply chain, and the safety system can survive scrutiny right now. Recent deals show why buyers care about that proof. Merck’s 2025 agreement to acquire Verona Pharma centered on Ohtuvayre, a COPD drug the FDA had approved in June 2024. Gilead’s 2024 acquisition of CymaBay came before seladelpar’s approval, but the deal was explicitly tied to an anticipated near-term FDA decision. Merck KGaA’s 2025 agreement to buy SpringWorks targeted a commercial-stage company with approved products already on the market. (businesswire.com) These are not science-fair bets. They are purchases of de-risked assets moving from regulatory success into commercial extraction. So the new dataset lands hardest with the people who run safety, quality, and regulatory operations. They are being asked to support a launch, satisfy the FDA, generate clean real-world evidence, and keep the organization transaction-ready at the same time. In that compressed window, a missed inspection observation or a sloppy post-market signal process is not just a compliance problem. It can change who buys the company, when they buy it, and at what price. The first FDA approval still looks like a finish line from the outside. Inside biotech, it increasingly looks like a 33-month countdown.